Drug Patents owned by Genentech
1. List of Erivedge drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7888364 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Nov, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9790183 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Sep, 2025
(2 years from now) | |
| US9278961 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Dec, 2028
(5 years from now) | |
Drugs and Companies using VISMODEGIB ingredient
Market Authorisation Date: 30 January, 2012
Treatment: Method of using vismodegib to treat basal cell carcinoma; Method of using vismodegib to treat cancer in a mammal
Dosage: CAPSULE;ORAL
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic